The House Resolution, introduced by Representative Domangue, urges the Louisiana Department of Health to conduct a study examining the potential correlation between medications used in gender-affirming hormone therapy and the incidence of psychosis and related psychiatric conditions in individuals aged 26 and younger. The resolution highlights the importance of understanding the health and well-being of young residents, particularly in light of concerns regarding the psychological side effects associated with certain hormone therapies, which may include androgen blockers, estrogen, testosterone, and puberty blockers.

The study is expected to include a review of peer-reviewed medical literature on psychiatric outcomes related to these therapies, an examination of adverse event data concerning various psychiatric symptoms, and consultations with a range of healthcare professionals. The Louisiana Department of Health is tasked with submitting a written report of its findings and any recommendations to the House Committee on Health and Welfare by February 1, 2027. This initiative aims to provide valuable insights for healthcare professionals, patients, and families regarding the mental health implications of gender-affirming treatments.